SR T100

Drug Profile

SR T100

Alternative Names: SR-T100; SR-T100 gel

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G&E Herbal Biotechnology
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Condylomata acuminata
  • Phase 0 Vulvar intraepithelial neoplasia

Most Recent Events

  • 12 Sep 2017 SR T100 is still in phase II trials for Condylomata acuminata in Taiwan (Topical) (NCT01796821)
  • 31 Jul 2017 G&E Herbal Biotechnology withdraws a planned phase II trial for Common warts in Taiwan (Topical) due to budget issues (NCT01796795)
  • 01 Nov 2015 G&E Herbal Biotechnology completes a phase III trial in Actinic keratosis in Taiwan (Topical, gel) (NCT01493921)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top